Home|Journals|Articles by Year|Audio Abstracts

Original Article

J App Pharm Sci. 2023; 13(8): 167-176

Evaluation of regression of diabetes-induced nephropathy and vascular dysfunction in rats by montelukast via antioxidative and anti-inflammatory actions

Hanan S. Anbar, George S. G. Shehatou, Mona Abdel-Rahim, Ghada M. Suddek, Nariman M. Gameil.

Cited by 0 Articles

This research investigated the effects of montelukast (MONT), a leukotriene receptor antagonist, on diabetes-associated nephropathy and vascular dysfunction in streptozotocin (STZ) diabetic rats.
STZ-diabetic Sprague-Dawley rats (a single STZ injection, 50 mg/kg, i.p) were randomly allocated into three groups (n=8 each): STZ (received the drug vehicle), STZ-LOS (received losartan (LOS), 25 mg/kg/day, orally) and STZ-MONT (received MONT, 10 mg/kg/day, orally). Drug administration started 2 weeks after induction of diabetes and continued till the end of the experiments (10 weeks). A group of age-matched normal rats was set as control. After 70 days, urine and serum specimens were obtained for biochemical assessments. Moreover, In renal and/or aortic tissue homogenates, levels of reduced glutathione (GSH), superoxide dismutase (SOD), malondialdehyde (MDA), nitric oxide (NO), tumor necrosis factorα (TNF-α), and transforming growth factor-β1 (TGF-β1) were assessed. Pathological alterations in diabetic kidneys and aorta were examined and vascular reactivity of isolated aortic rings was investigated.
MONT attenuated body weight loss, reduced diabetic renal hypertrophy, ameliorated glycated hemoglobin levels, improved renal functions, and lessened renal and aortic oxidative stress in STZ rats. Moreover, MONT reduced kidney levels of TNF-α and TGF-β1 compared to the untreated STZ group. MONT reduced histopathological alterations in renal tissues and diminished aortic medial thickness in diabetic animals. MONT also attenuated enhanced contractile reactivity of STZ aortas to phenylephrine. The effects of MONT were comparable to or surpassed, those brought about by LOS treatment.
In conclusion, MONT could offer comparable renoprotective and vasculoprotective effects to LOS in type 1 diabetic rats.

Key words: Diabetes; Nephropathy; Montelukast; Oxidative stress; TNF-α; TGF-β1; Vascular dysfunction

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.